Can I not stop taking Riboxil/Calilon once I take it?

Ribociclib/Calilon (Ribociclib) is a selective CDK4/6 inhibitor. Its efficacy relies on the continuous inhibition of the activity of cyclin-dependent kinases 4 and 6, thereby preventing cancer cells from entering the S phase from the G1 phase and slowing down tumor proliferation. This mechanism of action determines that while patients are taking Riboxil, it is generally not recommended to interrupt the medication on their own or at will. Clinical experience shows that if treatment is stopped early or at will, the tumor may progress rapidly and the risk of disease recurrence increases, thus affecting the long-term treatment effect.

Riboxiclib is often used in combination with endocrine therapy, such as letrozole or anastrozole. The combined treatment model requires drugs to maintain stable blood concentrations in order to continuously inhibit cancer cell proliferation and achieve optimal efficacy. Patients need to undergo regular blood routine, liver function and electrocardiogram monitoring during medication to detect possible hematological or cardiac adverse reactions. If serious adverse reactions occur, doctors will adjust the dose or temporarily discontinue the drug based on the specific situation rather than completely interrupting treatment.

In addition, the safety of long-term use of Riboxil has been fully verified in overseas practice. The oral administration method is convenient and well tolerated, allowing patients to maintain drug treatment for a long time and achieve dual benefits of disease control and quality of life. Research shows that continuous treatment not only delays tumor progression, but also reduces the risk of recurrence, providing a more stable and sustainable disease management solution for patients with advanced breast cancer.

It is very important for breast cancer patients to follow the doctor's instructions and not to reduce the dose or interrupt treatment at will. Medical staff will provide individualized medication plans and monitoring plans based on the patient's physique, blood indicators and changes in condition, thereby reducing the risk of potential side effects while ensuring the efficacy. In short, long-term and continuous use is the key to the optimal efficacy of reboxil, and it is also an important principle that cannot be ignored in the management of advanced breast cancer.

Reference materials:https://us.kisqali.com/